MX2016013048A - Combinación de inhibidor de egfr e inhibidor de mek para el uso en el tratamiento de cáncer mutado por nras. - Google Patents
Combinación de inhibidor de egfr e inhibidor de mek para el uso en el tratamiento de cáncer mutado por nras.Info
- Publication number
- MX2016013048A MX2016013048A MX2016013048A MX2016013048A MX2016013048A MX 2016013048 A MX2016013048 A MX 2016013048A MX 2016013048 A MX2016013048 A MX 2016013048A MX 2016013048 A MX2016013048 A MX 2016013048A MX 2016013048 A MX2016013048 A MX 2016013048A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- inhibitor
- combination
- nras
- mutated cancer
- Prior art date
Links
- 101150073096 NRAS gene Proteins 0.000 title abstract 3
- 229940124647 MEK inhibitor Drugs 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 229940121647 egfr inhibitor Drugs 0.000 title abstract 2
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- 102100039788 GTPase NRas Human genes 0.000 abstract 3
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 abstract 3
- 230000035772 mutation Effects 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 102200006531 rs121913529 Human genes 0.000 abstract 2
- 102200006651 rs121917756 Human genes 0.000 abstract 2
- 238000011275 oncology therapy Methods 0.000 abstract 1
- 230000008261 resistance mechanism Effects 0.000 abstract 1
- 102200006537 rs121913529 Human genes 0.000 abstract 1
- 102200006539 rs121913529 Human genes 0.000 abstract 1
- 102200006538 rs121913530 Human genes 0.000 abstract 1
- 102200006540 rs121913530 Human genes 0.000 abstract 1
- 102200006541 rs121913530 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La invención se refiere a los métodos para identificar resistencia a la terapia para cáncer, mediante la identificación de una mutación E63K NRAS, una mutación G12V NRAS o una ganancia del número de copias del gen NRAS. Un aspecto adicional de la invención se refiere a métodos de tratamiento que pueden superar tales mecanismos de resistencia, que implican el uso de un inhibidor de EGFR en combinación con un inhibidor de MEK para el tratamiento de cánceres que implican una mutación NRAS seleccionada de E63K, G12V, G12R, G12A, G12D, G12S y G12C, y/o cáncer que implica una ganancia del número de copias del gen NRAS.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461975088P | 2014-04-04 | 2014-04-04 | |
US201462013573P | 2014-06-18 | 2014-06-18 | |
PCT/GB2015/051042 WO2015150826A1 (en) | 2014-04-04 | 2015-04-02 | Combination of egfr inhibitor and mek inhibitor for use in the treatment of nras mutated cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016013048A true MX2016013048A (es) | 2017-04-27 |
MX369111B MX369111B (es) | 2019-10-29 |
Family
ID=52824498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016013048A MX369111B (es) | 2014-04-04 | 2015-04-02 | Combinación de inhibidor de egfr e inhibidor de mek para el uso en el tratamiento de cáncer mutado por nras. |
Country Status (15)
Country | Link |
---|---|
US (2) | US20200237758A1 (es) |
EP (1) | EP3125885B1 (es) |
JP (1) | JP6549147B2 (es) |
KR (1) | KR102406334B1 (es) |
CN (1) | CN106456774A (es) |
AU (1) | AU2015242407B2 (es) |
CA (1) | CA2943402C (es) |
DK (1) | DK3125885T3 (es) |
ES (1) | ES2890556T3 (es) |
HU (1) | HUE055747T2 (es) |
MA (1) | MA39841A (es) |
MX (1) | MX369111B (es) |
PL (1) | PL3125885T3 (es) |
RU (1) | RU2683276C2 (es) |
WO (1) | WO2015150826A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109311858B (zh) | 2016-05-26 | 2021-12-03 | 里科瑞尔姆Ip控股有限责任公司 | Egfr抑制剂化合物 |
WO2018218633A1 (en) * | 2017-06-02 | 2018-12-06 | Beijing Percans Oncology Co. Ltd. | Combination therapies for treating cancers |
WO2019195959A1 (en) | 2018-04-08 | 2019-10-17 | Cothera Biosciences, Inc. | Combination therapy for cancers with braf mutation |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005534623A (ja) * | 2002-04-08 | 2005-11-17 | スミスクライン ビーチャム コーポレーション | Erbファミリーの阻害剤並びにraf及び/又はras阻害剤を投与することを含む癌の治療法 |
JP2012508240A (ja) * | 2008-11-11 | 2012-04-05 | イーライ リリー アンド カンパニー | P70s6キナーゼ阻害剤およびegfr阻害剤の併用療法 |
EP3686193B1 (en) * | 2011-07-27 | 2022-03-02 | Astrazeneca AB | 2-(2,4,5-substituted-anilino)pyrimidine compounds |
RU2620068C2 (ru) * | 2011-11-23 | 2017-05-22 | МЕДИММЬЮН, ЭлЭлСи | Связывающие молекулы, специфичные по отношению к her3, и их применения |
WO2013170066A1 (en) * | 2012-05-09 | 2013-11-14 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Peptides for the treatment of cancer |
EP2884971A4 (en) * | 2012-08-16 | 2016-01-06 | Ohio State Innovation Foundation | STAT3 INHIBITORS AND THEIR ANTICANCER USE |
US20140066465A1 (en) * | 2012-09-04 | 2014-03-06 | The Cleveland Clinic Foundation | CANCER TREATMENT USING TYROSINE KINASE AND NF-kB INHIBITORS |
-
2015
- 2015-04-02 WO PCT/GB2015/051042 patent/WO2015150826A1/en active Application Filing
- 2015-04-02 JP JP2016560813A patent/JP6549147B2/ja active Active
- 2015-04-02 PL PL15715805T patent/PL3125885T3/pl unknown
- 2015-04-02 AU AU2015242407A patent/AU2015242407B2/en active Active
- 2015-04-02 US US15/301,448 patent/US20200237758A1/en not_active Abandoned
- 2015-04-02 DK DK15715805.6T patent/DK3125885T3/da active
- 2015-04-02 HU HUE15715805A patent/HUE055747T2/hu unknown
- 2015-04-02 ES ES15715805T patent/ES2890556T3/es active Active
- 2015-04-02 CA CA2943402A patent/CA2943402C/en active Active
- 2015-04-02 KR KR1020167030569A patent/KR102406334B1/ko active IP Right Grant
- 2015-04-02 CN CN201580022665.5A patent/CN106456774A/zh active Pending
- 2015-04-02 MX MX2016013048A patent/MX369111B/es active IP Right Grant
- 2015-04-02 EP EP15715805.6A patent/EP3125885B1/en active Active
- 2015-04-02 RU RU2016140626A patent/RU2683276C2/ru active
- 2015-04-02 MA MA039841A patent/MA39841A/fr unknown
-
2020
- 2020-12-16 US US17/123,777 patent/US20210177844A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR102406334B1 (ko) | 2022-06-07 |
EP3125885B1 (en) | 2021-06-30 |
US20200237758A1 (en) | 2020-07-30 |
CA2943402A1 (en) | 2015-10-08 |
RU2016140626A3 (es) | 2018-10-23 |
EP3125885A1 (en) | 2017-02-08 |
KR20160135362A (ko) | 2016-11-25 |
RU2683276C2 (ru) | 2019-03-27 |
JP6549147B2 (ja) | 2019-07-24 |
HUE055747T2 (hu) | 2021-12-28 |
AU2015242407B2 (en) | 2017-11-09 |
RU2016140626A (ru) | 2018-05-07 |
US20210177844A1 (en) | 2021-06-17 |
PL3125885T3 (pl) | 2021-12-06 |
AU2015242407A1 (en) | 2016-10-13 |
DK3125885T3 (da) | 2021-09-27 |
MA39841A (fr) | 2017-02-08 |
CA2943402C (en) | 2022-12-13 |
JP2017511341A (ja) | 2017-04-20 |
CN106456774A (zh) | 2017-02-22 |
ES2890556T3 (es) | 2022-01-20 |
WO2015150826A1 (en) | 2015-10-08 |
MX369111B (es) | 2019-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021006234A (es) | Perfilado molecular de proxima generacion. | |
EP3287774B8 (en) | Data processing device for x-ray examination, and computer implemented data processing method | |
MX359781B (es) | Método y dispositivo para ocultar información de privacidad. | |
MX2018002741A (es) | Metodo y aparato para determinar datos volumetricos de una caracteristica anatomica predeterminada. | |
MX368099B (es) | Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib. | |
MX2018010261A (es) | Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos. | |
GB2553556B (en) | Data processing apparatuses, methods, computer programs and computer-readable media | |
MX2019013634A (es) | Composiciones y metodos para tratar cancer con mutaciones de braf atipicas. | |
MX2017008421A (es) | Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga. | |
MX2016002273A (es) | Tratamiento de cancer con una combinacion de un antagonista de proteina de muerte programada 1 y dinaciclib. | |
WO2016109782A3 (en) | Methods and compositions for detecting colorectal neoplasias | |
MX2016012697A (es) | Perfiles de marcadores biologicos de proteina para detectar tumores colorrectales. | |
EP3555308C0 (en) | EPIGENETIC MARKERS AND ASSOCIATED METHODS AND MEANS OF DETECTION AND MANAGEMENT OF OVARIAN CANCER | |
IL267315A (en) | Methods of determining colorectal cancer status in an individual | |
GB2554065B (en) | Data processing apparatuses, methods, computer programs and computer-readable media | |
EP3271483A4 (en) | Methods and materials for assessing and treating cancer | |
NZ752443A (en) | Lasofoxifene treatment of er+ breast cancer | |
MX2016013048A (es) | Combinación de inhibidor de egfr e inhibidor de mek para el uso en el tratamiento de cáncer mutado por nras. | |
EP3521818A4 (en) | COLORECTAL CANCER DIAGNOSIS DEVICE AND METHOD FOR PROVIDING COLORECTAL CANCER DIAGNOSIS INFORMATION | |
BR112018013269A2 (pt) | composições e métodos para a avaliação do risco de ocorrência do câncer | |
GB2553557B (en) | Data processing apparatuses, methods, computer programs and computer-readable media | |
MX2019001214A (es) | Metodos para el diagnostico de neoplasia de origen ginecologico. | |
Pennsylvania Counseling Association | 2016-05-21 PCA PACES Report, May 3, 2016 | |
AU2016904497A0 (en) | Methods and apparatus for managing electronic confidential information | |
Pennsylvania Counseling Association | 2015-11-06 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |